drugset

drugset / Trial / NCT06471361

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

NCT06471361 ↗

Phase 3 Completed 31 enrolled UCB Biopharma SRL

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.

Timeline

Start: 2024-08-27
Primary completion: 2025-01-28
Completion: 2025-02-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zilucoplan	Peptide	—	Subcutaneous

Indications